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Abstract
Background: Phage display technology is a powerful new tool for making antibodies outside the
immune system, thus avoiding the use of experimental animals. In the early days, it was postulated
that this technique would eventually replace hybridoma technology and animal immunisations.
However, since this technology emerged more than 20 years ago, there have only been a handful
reports on the construction and application of phage display antibody libraries world-wide.
Results: Here we report the simplest and highly efficient method for the construction of a highly
useful human single chain variable fragment (scFv) library. The least number of oligonucleotide
primers, electroporations and ligation reactions were used to generate a library of 1.5 × 108
individual clones, without generation of sub-libraries. All possible combinations of heavy and light
chains, among all immunoglobulin isotypes, were included by using a mixture of primers and
overlapping extension PCR. The key difference from other similar libraries was the highest diversity
of variable gene repertoires, which was derived from 140 non-immunized human donors. A wide
variety of antigens were successfully used to affinity select specific binders. These included pure
recombinant proteins, a hapten and complex antigens such as viral coat proteins, crude snake
venom and cancer cell surface antigens. In particular, we were able to use standard bio-panning
method to isolate antibody that can bind to soluble Aflatoxin B1, when using BSA-conjugated toxin
as a target, as demonstrated by inhibition ELISA.
Conclusion: These results suggested that by using an optimized protocol and very high repertoire
diversity, a compact and efficient phage antibody library can be generated. This advanced method
could be adopted by any molecular biology laboratory to generate both naïve or immunized
libraries for particular targets as well as for high-throughput applications.
Background
Monoclonal antibodies have become important tools in
several fields, including molecular biology, pharmaceuti-
cal and medical research, as well as in the treatment of dis-
eases such as cancer and infectious diseases [1-3]. Since
the advent of antibody technology, antibody production
Published: 29 January 2009
BMC Biotechnology 2009, 9:6 doi:10.1186/1472-6750-9-6
Received: 14 August 2008
Accepted: 29 January 2009
This article is available from: http://www.biomedcentral.com/1472-6750/9/6
© 2009 Pansri et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Biotechnology 2009, 9:6 http://www.biomedcentral.com/1472-6750/9/6
Page 2 of 16
(page number not for citation purposes)
has moved from hybridoma technology to recombinant
DNA methodology. The advantages of recombinant anti-
bodies are several folds, (i) antibodies can be produced in
bacteria, yeast or plant [4-6], (ii) immunization is not
required and (iii) intrinsic properties such as immuno-
genicity, affinity, specificity and stability of antibodies can
be improved by various mutagenesis technologies [7-9].
In the past two decade, advances in phage display and
antibody engineering have led to the development of
phage-displayed antibody technology [10,11]. This tech-
nology allows one to isolate antibodies directly from
diverse repertoires of antibody genes, generating high-
affinity binding sites without the constraint imposed by
classical method for generating either polyclonal or mon-
oclonal antibody [12-16]. Since the method does not
depend on an animal's immune system, antibodies to a
wide variety of antigens, including the molecules that can-
not stimulate immune system of the animals such as non-
immunogenic, "self", cell surface or toxic antigens, can be
generated [16-18]. The antibodies can also be engineered
to contain in-built features that suit various downstream
applications [19] or converted into functional whole
immunoglobulin [20,21]. The antibody genes are
expressed and the gene products displayed on the surface
of filamentous bacteriophage as fusion proteins [7,11,22-
25]. This collection of phages is called a phage display
antibody library, where each phage particle displays a sin-
gle antibody. In order to construct a library, antibody
genes are fused to phage genes, thus creating a link
between antibody phenotype and its encoded genotype.
Antibody genes can be isolated from B-lymphocytes of
non-immunized donors, rendering a naïve library which
is a valuable source of human monoclonal antibodies
against various antigens [26]. Various formats of antigen-
binding fragments, including Fab and scFv have been
cloned and displayed on phage [27,28]. The advantage of
smaller antibody fragments is that they have high tissue
penetrability, while maintaining their affinity and specifi-
city [29-31]. They are also easier and faster to produce in
recombinant form. However, successful construction of a
human antibody phage library has been achieved only by
a small number of research groups [10,29,32]. One reason
may be because of the complexity and cost of generation
of the library, even though there have been some reports
describing optimized protocols for the generation of effi-
cient libraries [32,33].
Here we report a simple and highly efficient method for
the construction of a compact and highly useful scFv
human library. The library was based on the naïve human
re-arranged V-genes and assembled through the use of a
gene repertoire derived from 140 non-immunized
donors. All possible combinations of heavy and light
chains, among all immunoglobulin isotypes, were
included by using a mixture of primers and overlapping
extension PCR. The resulting variable gene repertoire were
cloned to form a moderate size library composed of 1.5 ×
108 individual clones from one ligation reaction. This rep-
ertoire was used for selection of specific binders to differ-
ent proteins, a hapten, and complex antigens i.e., viral
coat proteins, crude snake venom and cancer cell surface.
Binding specificity and sequence diversity among binders
were demonstrated.
Results
Construction of pMod1 phagemid
A novel phagemid vector, designated pMod1, for the con-
struction of phage-displayed scFv library was created (Fig-
ure 1). This vector was based on the phagemid vector,
pHage 3.2 (Maxim Biotech Inc, USA). A multiple cloning
site was introduced, containing five restriction recogni-
tion sties, of which SfiI and NotI were used for the inser-
tion of scFv gene repertoires. The gene III leader peptide
was used to direct the secretion of scFv, whereas ampicil-
lin resistant gene was used for the selection and mainte-
nance of the phagemid. The scFv gene was linked to the
hexahistidine tag followed by Myc epitope. The hexahisti-
dine tag can be used for one-step affinity purification with
immobilized metal affinity chromatography (IMAC),
whereas the Myc epitope can be recognized by 9E10 mon-
oclonal antibody for detection. An amber stop codon was
introduced between the Myc-tag and gene III, thus allow-
ing production of non-fused scFv by introduction of the
phagemid DNA in a non-suppressor E. coli strains
(HB2151).
Library construction
A diagram that outlines the construction of the compact
scFv antibody library is shown in Figure 2. Peripheral
blood from one hundred and forty healthy non-immu-
nized donors was collected into four pools, according to
different blood groups. These include adults at the age
between 17–50, both male and female, in Nakhon Ratch-
asima province. The bloods were tested and discharged
from the Thai Red Cross Society blood donation unit.
Total RNA was prepared from the B lymphocytes and
pooled together before being used as templates for the
construction of V-genes repertoire. A mix of oligo-dT18
and random hexamers were used to synthesize cDNA, so
that all five antibody isotypes could potentially be repre-
sented. In order to reduce amplification bias, we per-
formed 75 independent PCR reactions to amplify V gene
segments, using all possible combinations within a
primer set (Table 1). The primer sequences, which in the-
ory encompass the entire repertoire of human antibody
genes, were obtained from V BASE [34], and modified
according to previously published protocols [14,32]. The
PCR reactions included six VH forward primers (VH5'SfiI)
paired with four VH reverse primers (VH3'link) which gen-
erated a total of twenty-four reactions; whereas six Vκ for-BMC Biotechnology 2009, 9:6 http://www.biomedcentral.com/1472-6750/9/6
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ward primers (VL5'link-κ) paired with five Vκ  reverse
primers (VL3'NotI-κ) generated a total of thirty reactions;
and seven Vλ forward primers (VL5'link-λ) paired with
three Vλ reverse primers (VL3'NotI-λ) generated a total of
twenty-one reactions. The PCRs led to the representation
in the repertoire of variable regions derived from all con-
ceivable framework assemblies.
A total of 33 primers were used for the construction of the
scFv library. All primers contained either SfiI or NotI rec-
ognition sites or linker sequence as illustrated in Figure 2
and detailed in Table 1. The final pull-through PCR could
be done with two primers (PTfw & PTrv) compatible to
the 5' SfiI or 3'NotI segments of the heavy and light chain
gene repertoires. We found that it was not necessary to
add extra nucleotides 5' to the recognition sites as previ-
ous published [32,33], provided that sufficient incuba-
Map of phagemid vector, pMod1, for the construction of scFv phage-display library Figure 1
Map of phagemid vector, pMod1, for the construction of scFv phage-display library. This 4541-base-pair (bp) vec-
tor was modified from pHage 3.2 (Maxim Biotech, Inc.), which was derived from M13. Transcription is under control of the lac 
promoter. The ampicillin resistant gene is for the selection and maintenance of the phagemid. The phagemid carries Fi and 
ColEi origin of replication for amplification in phage and E. coli. The secretion of the scFv fragment is directed by gene III signal 
peptide. The scFv genes are cloned between SfiI and NotI for display on the phage coat protein, pIII. An amber stop codon in 
frame with and immediately following hexahistidine-tag and Myc-tag permit the expression of scFv as a fusion with gene III in an 
amber suppressor host (TG1) or as a fusion with only the 6 × His-tag and Myc-tag in a non-suppressor host strain (HB2151). 
The scFv fragment is fused with hexahistidine tag and Myc tag for affinity purification and immuno-detection, respectively. The 
coding region of a gene III leader peptide and the multiple cloning sites is shown with the position of 6 × His, Myc tags and 
amber stop codon. The map was not drawn to scale. The sequences around the cloning sites were shown at the bottom of the 
figure.
Amber codon
pMOD1
4541 bp
Fi ori
ColE1 ori
Gene III
Gene III  leader
Sfi I
Sal I
Nco I
Xho I
Not I
Apa I
his Tag
Myc-Tag
Ampicillin
r
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tion period (overnight) was performed for each digestion
reaction. After the final scFv gene repertoires had been
sequentially digested with SfiI and NotI, they could be
ligated directly into pre-digested and dephosphorylated
phagemid. From one ligation reaction and two electropo-
rations, we were able to obtain the final compact scFv
library consisting of 1.5 × 108 different scFv molecules
with 0.04% of clones from no-insert ligation.
Diversity of antibody fragments
To analyze the diversity of the scFv repertoire and the
quality of the primary library, DNA segments encoding
the scFv genes from fifteen randomly picked clones were
examined. The phagemid DNA of these clones were
amplified by PCR and digested with BstNI, and their fin-
gerprint patterns were compared. Thirteen different pat-
terns were identified as shown in Figure 3. DNA sequence
analysis of ten different clones revealed that the scFv frag-
ments were all in-frame [see Additional file 1]. The finger-
prints of clone3 and clone8 were apparently identical;
although their nucleotide and amino acid sequences were
different. The variable regions were derived from thirteen
different V gene families, including all six VH gene families
(VH1, VH2, VH3, VH4, VH5, and VH6) and seven VL gene
families of both kappa and lambda light chain (Vκ2, Vκ3,
Vκ4 and Vλ2, Vλ3, Vλ5, Vλ6). The V-gene segments such as
VH3DP47, VλDPL16, and Vκ3DPK22 which are most often
used in the natural B cell repertoire [17,33,35] were
included in the unselected library as well as other less fre-
quent segments. The CDR3 of VH sequences were highly
Table 1: Primers for the Construction of Human scFv Phage Display Library
Primer Sequence
VH5'Sfi 5' CCTTTCTATGCGGCCCAGCCGGCCATGGCCCAGGTGCAGCTGGTGCAGTCTGG 3'
5' CCTTTCTATGCGGCCCAGCCGGCCATGGCCGAGGTACAGCTGCAGCAGTCAGG 3'
5' CCTTTCTATGCGGCCCAGCCGGCCATGGCCCAGGTCAACTTAAGGGAGTCTGG 3'
5' GCCCAGCCGGCCATGGCCGAGGTGCAGCTGGTGGAGTCTGG 3'
5' GCCCAGCCGGCCATGGCCCAGGTGCAGCTGCAGGAGTCGGG 3'
5' GCCCAGCCGGCCATGGCCGAGGTGCAGCTGTTGCAGTCTGC 3'
VH3'link 5' ACCAGAGCCGCCGCCGCCGCTACCACCACCACCTGAGGAGACGGTGACCAGGGTGCC 3'
5' ACCAGAGCCGCCGCCGCCGCTACCACCACCACCTGAGGAGACGGTGACCGTGGTCCC 3'
5' ACCAGAGCCGCCGCCGCCGCTACCACCACCACCTGAAGAGACGGTGACCATTGTCCC 3'
5' ACCAGAGCCGCCGCCGCCGCTACCACCACCACCTGAGGAGACGGTGACCAGGGTTCC 3'
VL5'link-κ 5' AGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCGACATCCAGATGACCCAGTCTCC 3'
5' AGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCGAAATTGTGCTGACTCAGTCTCC 3'
5' AGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCGATGTTGTGATGACTCAGTCTCC 3'
5' AGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCGAAATTGTGTTGACGCAGTCTCC 3'
5' AGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCGACATCGTGATGACCCAGTCTCC 3'
5' AGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCGAAACGACACTCACGCAGTCTCC 3'
VL5'link-λ 5' AGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCAATTTTATGCTGACTCAGCCCCA 3'
5' AGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCCAGTCTGTGTTGACGCAGCCGCC 3'
5' AGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCCAGTCTGCCCTGACTCAGCCTGC 3'
5' AGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCTCCTATGTGCTGACTCAGCCACC 3'
5' AGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCTCTTCTGAGCTGACTCAGGACCC 3'
5' AGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCCACGTTATACTGACTCAACCGCC 3'
5' AGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCCAGGCTGTGCTCACTCAGCCGTC 3'
VL3'NotI-κ 5' CAGTCATTCTCGACTTGCGGCCGCACGTTTGATTTCCAGCTTGGTCCC 3'
5' CAGTCATTCTCGACTTGCGGCCGCACGTTTAATCTCCAGTCGTGTCCC 3'
5' CAGTCATTCTCGACTTGCGGCCGCACGTTTGATCTCCAGCTTGGTCCC 3'
5' CTCGACTTGCGGCCGCACGTTTGATATCCACTTTGGTCCC 3'
5' CTCGACTTGCGGCCGCACGTTTGATCTCCACCTTGGTCCC 3'
VL3'NotI-λ 5' CAGTCATTCTCGACTTGCGGCCGCACCTAAAACGGTGAGCTGGGTCCC 3'
5' CTCGACTTGCGGCCGCACCTAGGACGGTGACCTTGGTCCC 3'
5' CTCGACTTGCGGCCGCACCTAGGACGGTCAGCTTGGTCCC 3'
PTfw 5' CCTTTCTATGCGGCCCAGCCGGCCATGGCC 3'
PTrv 5' CAGTCATTCTCGACTTGCGGCCGCACG 3'
*Bold fonts indicate sequence complementary to the V-gene segments. Recognition sites for restriction enzymes (SfiI/NotI), and linker sequence are 
italicised.BMC Biotechnology 2009, 9:6 http://www.biomedcentral.com/1472-6750/9/6
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diverse, with lengths between 5 to 19 amino acids. The VL
sequences had between 8 and 13 amino acids in their
CDR3 regions. Thus, the scFv gene fragments were distrib-
uted across the full repertoire of antibody germ line genes.
The number of different amino acids from germ line var-
ied from 0–24 amino acids, suggesting that both germ line
B genes and antibodies from secondary immune
responses were included in the library [see Additional file
Schematic outline of the strategy used for the construction of compact scFv library Figure 2
Schematic outline of the strategy used for the construction of compact scFv library. The total RNA was extracted 
from peripheral blood lymphocyte (PBL) of 140 non-immunized healthy donors. cDNA was synthesized by using a mix of ran-
dom hexamer and oligo dT18. The locations of all PCR primers on the two variable region genes are shown. The list of all prim-
ers used for the construction of the library is given in Table 1. Three step PCR reactions were performed. The first PCR step 
comprises 75 reactions for amplification of V gene repertoire. The second and third PCRs link and amplify full-length scFv gene 
repertoire, which were cloned into pMod1 phagemid. The DNA sequence encoding the flexible linker is depicted in detail.
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1]. Analysis of germ line family was done by using Ig
BLAST [36], and DNA Plot program [34].
Selection of scFv antibodies against various antigens
Because the library is compact and a protease sensitive
helper phage, KM13 [37] was used during bio-panning,
only one or two round of selection were performed on
eight different antigens. These antigens include pure pro-
teins [BSA, GST, Amylase], hapten [BSA-conjugated Afla-
toxin B1], and very complex antigens [snake venom
(cobra and green viper), rabies viruses, and cholangiocar-
cinoma (bile duct cancer) cells]. To reduce the amount of
antigens needed for each bio-panning, all antigens were
immobilized on wells of 96-well ELSIA plate (except for
cancer cells that were grown on 5-ml flask). The numbers
of clones obtained from the first rounds of selection were
varied, as shown in Table 2. After the first round of selec-
tion with a particular antigen, up to 96 phage clones were
picked and their binding specificity determined by phage
ELISA. We were able to obtain at least one specific phage
clone for all antigens, except for crude green pit viper
snake venom. An additional round of panning increased
the ratio of binders but did not increase the chance to
obtain clones not already detected after the round one. As
demonstrated in the case of snake venom, the nine clones
that were isolated from the second round of panning were
all the same and identical to the clone obtained from the
first round of selection. For attenuated virus, six out of
seven clones from the second round of panning were
identical. The number of clones obtained from the first
round of panning varied, depending on the type of the
antigens and the number of washings. We found that the
most appropriate number of clones after the first round of
selection should vary between 100–1,000 colonies. This
result suggested that, for a compact naïve library like in
this report, one round of selection is sufficient and most
appropriate to obtain scFv antibodies with maximal diver-
sity.
Characterization of selected scFv antibodies
The binding of scFv to antigens was highly specific even
though the antigens were very complex. For example, the
selected anti-cobra venom scFv did not cross react with
green viper snake venom (Figure 4, panel A). Another
example of scFv specificity is illustrated by the selection
against bile duct cancer cells. One of the two clones dem-
onstrated higher specificity for a cholangiocarcinoma cell
line, when compared to COS-7 or HepG-2 cells (Figure 4,
panel B). This experiment was done without pre-incuba-
tion or subtraction with other cell lines, demonstrating
that it is possible to obtain highly specific antibodies
against a complex cell surface antigen by one round of
bio-panning using this compact library.
To determine the binding specificity of selected soluble
scFv fragments, E. coli HB2151 was infected with specific
phage selected on different antigens. HB2151, unlike TG-
1, is not able to suppress the amber stop codon upstream
of the gene III sequence in pMod1 vector, thus resulting in
expression of non-fused scFv. Most of these clones pro-
duced functional antibody fragments which were specific
to their antigen, readily detected in cell culture superna-
tants by ELISA, as summarized in Table 2.
DNA sequence analysis of selected scFv clones (Table 3)
revealed that VH genes were derived from three of the six
VH gene families (nos. 1, 3, and 4). Families 1 and 4 have
been shown to be predominating in previous reports
[33,35]. Comparison of the six VH sequences with their
closest germline V sequence using IgBLAST [36] and V
DNA fingerprinting of random clones from unselected library Figure 3
DNA fingerprinting of random clones from unselected library. Fifteen scFv gene fragments were amplified by PCR and 
digested with BstN1 at 60°C for 3 hours. The restriction patterns were analyzed on 2% agarose (* and # indicate similar pat-
terns).
M    1 2    3 4  5     6     7   8   9    10   11 12   13 14   15 **
##
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Table 2: Results of affinity selections with different targets
Antigens Round of 
panning
Number of
clone after 1st
round
Number of
binding phage
after 1st round
Number of 
binding phage 
after 2nd round
Number of 
soluble scFv 
fragments
Number of 
different scFv 
producing clone
Aflatoxin 1 2.5 × 102 4/56 - 3/4 3/3
Attenuated Rabies 
viruses
21 . 2  ×  1 0 3 1/96 7/96 8/8 2/8
Amylase 1 8.8 × 10 3/88 - 3/3 NA
BSA 1 2.0 × 103 6/96 - NA NA
Cobra snake 
venom
21 . 4  ×  1 0 4 1/96 9/96 3/3 1/10
Cholangiocarcino
ma cell KKU-100
12 . 2  ×  1 0 3 2/96 - NA 2/2
Green pit viper 
venom
25 . 1  ×  1 0 4 0/96 0/96 NA NA
GST 1 4.3 × 102 6/28 - NA NA
* The number of positive clones/the number of screened clones.
Binding specificity of selected phage Figure 4
Binding specificity of selected phage. Panel A shows the specific binding of phage selected from bio-panning against crude 
cobra snake venom. One hundred microgram of lyophilized crude cobra (Naja kaouthia) and green pit viper (Trimeresurus albo-
labris) snake venom were immobilized onto well of ELISA plate and incubated with the representative phage clone. Bound 
phage particles were detected by ELISA. The average OD405nm values and standard errors are shown. Panel B illustrates binding 
activity of two phage clones selected from bio-panning with cholangioma against different cell lines. KKU-100 is a human 
cholangiocarcinoma (bile duct cancer) cell line; COS-7 is an African Green Monkey SV40-transfected kidney fibroblast cell line; 
and HepG2 is a human hepatocellular liver carcinoma cell line. The cells were fixed with 4% paraformaldehyde before incubat-
ing with individual phage.
ABBMC Biotechnology 2009, 9:6 http://www.biomedcentral.com/1472-6750/9/6
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BASE [34] revealed that they were from 6 different germ-
line genes with various numbers of amino acid differing
compared to the germ line sequences, ranging from 1–14.
The VL genes were from four Vλ gene families (nos. 1, 2, 3,
and 6) and four different germ-line genes. It is interesting
that only one Vκ gene (Vκ1) family was obtained and they
were both from the same germ line genes, but different in
the number of different amino acids. The Vκ 1 family has
previously found to be most frequently used in other
reports as well [33,35]. The preferential usage of VH gene
family 1 and 3, especially segment DP47 has previously
been observed [17,33], this segment is most often used in
nature [17].
Analysis of the CDR3 regions of both VH and VL shows
considerable variability in their length, ranging from 6–19
amino acids, which is similar to the distribution of the
length of CDR3 in unselected library. The variations of the
CDR3 length in VH genes (6–19) were higher than that of
the VL genes (9–11). The VH CDR3 length and VH-gene
segment frequency is similar to those observed in natural
antibodies [38].
We have also observed one phenomenon similar to chain
promiscuity, where one light chain was found in combi-
nation with different heavy chain. The rabies B5 clone and
the Aflatoxin C3 clone used the same germ-line VL gene
(Vκ1, IGKV1D-39*01), but different VH genes (Table 3).
However, the CDR 3 regions of the two Vκ genes were dif-
ferent. This result suggested the framework of this Vκ gene
segment is favourable for phage-display format. The
number of different amino acids from germ line of the six
selected clones varied from 1–16 amino acids, as seen in
unselected library. This result suggested that both germ
line B genes and antibodies from secondary immune
responses were selected from the bio-panning. The sum-
mary of DNA sequence analysis of all six selected scFv
clones is shown in Table 3.
Analysis of Aflatoxin-scFv antibodies by competitive ELISA
Normally antibodies are selected by bio-panning against
hapten conjugated to immobilizing molecules such as
BSA, thus in many cases anti-hapten antibodies cannot
recognize free haptens [39]. However, in case of haptens
such as Aflatoxin, it is essential for most applications that
the antibody recognizes the soluble form of the hapten
[40,41]. In this report we demonstrated that by using our
compact scFv library and a simple bio-panning method,
we were able to obtain three phage clones that could inter-
act specifically with BSA-conjugated Aflatoxin B1, and one
of these clones could interact specifically with soluble
form of AflatoxinB1, as demonstrated by inhibition ELISA
(Figure 5). This type of assay has been used as an indirect
method to estimate the binding affinity of an antibody
[42].
Discussion
Phage display antibody technology has become increas-
ing popular for creating binding sites for use in all areas of
research, and in medical and industrial applications.
There are several examples of successful isolation of anti-
bodies against various antigens from different phage dis-
played antibody libraries [11,17,33,35,43], including
high throughput selection [44]. Unfortunately, the librar-
ies are not available commercially; any laboratories that
are interested in using this technique are required to con-
struct a library by themselves, or obtained existing librar-
ies for research with restrictions. Of the two types of phage
Table 3: Sequence diversity of antibody fragments selected against four different antigens
Clone Family CDR3 Germline Amino acids differences from germline
VH gene
Aflatoxin C3 VH1 ADDYGSGSYGFDY IGHV1-3*01 (DP25) 1
Aflatoxin C5 VH3 SRVGLWGPRYYYYYGMDVW IGHV3-23*04 (DP47) 4
Aflatoxin D2 VH1 GGPLDY IGHV1-45*02 (DP4) 5
Rabies D7 VH1 GGNFDY IGHV1-18*01 (DP14) 2
Rabies B5 VH3 GYATFDY IGHV3-23*01 (DP47) 7
Cobra D11 VH4 HGRDTSGYTMDYFDS IGHV4-59*07 (H4) 14
Carcinoma C4 VH3 DRGKYPGDGMGV IGHV3-23*01 (DP47) 6
VL gene
Aflatoxin C3 VK1 QQSYSTPYA IGKV1D-39*01 (DPK9) 4
Aflatoxin C5 VL3 QVWDRDSRTIV IGLV3-9*01 (V2-6) 16
Aflatoxin D2 VL2 SSYAGSNNLV IGLV2-8*01 (V1-2) 3
Rabies D7 VL1 AAWDDSLSGPV IGLV1-47*01 (DPL3) 2
Rabies B5 VK1 QQYSYNPYT IGKV1D-39*01 (DPK9) 1
Cobra D11 VL6 QSYDSSNRV IGLV6-57*01 (V1-22) 5
Carcinoma C4 VL1 AAWDDSLNGYV IGLV1-44*01 (DPL2) 2
* CDR3 sequence and V-gene segment usage for both heavy and light chains of the selected antibody are reported. Sequence analysis was done by 
Ig BLAST [36] and DNA Plot program [34] (shown in parenthesis).BMC Biotechnology 2009, 9:6 http://www.biomedcentral.com/1472-6750/9/6
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antibody libraries (immunized and non-immunized
libraries), the nonimmune library is of more general use,
because it can be applied to generate antibodies to any
desired antigen [12,28,33,35]. These "naive" libraries nor-
mally has been constructed from the light-chain and
heavy-chain IgM-V-gene pools of B cells isolated from
peripheral blood lymphocytes, bone marrow, or spleen
cells of nonimmunized healthy donors [13,17,44]. How-
ever, it has been reported that the diversity of the library
could also be maximized by using random hexamers to
prime cDNA synthesis, so that all five antibody classes
could potentially be represented [35]. Since the whole
antibodies cannot be functionally expressed in bacteria,
only the antibody fragments that contain the binding
regions are displayed on the surface of the bacteriophage
[10]. Most of the phage libraries that have been con-
structed display the antibody fragment on the surface of
the phage minor coat proteins (pIII). It has been shown
Inhibition ELISA of anti-Aflatoxin B1 antibody Figure 5
Inhibition ELISA of anti-Aflatoxin B1 antibody. Various 1:2 dilutions of soluble Aflatoxin B1 from 5.0–0.039 μg/ml in 2% 
MPBS were incubated with three selected Phage (C3, C5, D2) at 37°C for 30 min before adding into wells of Immuno 96 
MicroWell™ Plates, coated with 4 μg/ml BSA-conjugated AlatoxinB1. After 1 hr of incubation, the plates were washed three 
times with PBS-T followed by 3 times with PBS. Bound phage were detected with anti-M13 phage-horseradish peroxidase 
(HRP) conjugate, using ABTS (2,2-azino-di-3-ethyl-benzthiazoine-6-sulfonate) as a substrate. The average absorbance at a 
wavelength of 405 nm and S.D. are shown.BMC Biotechnology 2009, 9:6 http://www.biomedcentral.com/1472-6750/9/6
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that both Fab [27,45] and scFv [11,13,23] can be
expressed in the surface of M13 without apparent loss of
the antibody's specificity and affinity. Since the scFv for-
mat has been shown to be more efficient for display on
phage coat [33] and the aim of this research was to
develop the most efficient method to construct a compact
human antibody, the scFv format was chosen.
Several strategies have been described for producing anti-
body phage display library in scFv format but it is difficult
to define the minimal repertoire size needed to retrieve
good binders to antigens. Many approaches have been
proposed to improve phage displayed human antibody
repertoires, mainly by increasing the library sizes [17,35],
by sophisticated in vivo (Cre-lox) recombination method
[17], and by improving cloning steps [33,35]. In this
study, we describe a simple and highly efficient method to
construct a compact human scFv phage library, by modi-
fication of several previously published protocols
[15,32,46]. Our method needs the least number of oligo-
nucleotide primers (33 primers). The lab of J.D. Marks
used 66 primers to construct a naive library [13] while the
lab of J. McCafferty used 89 primers [44]. In these reports,
two sets of primers were used to construct the library. The
first set allow the amplification of the VH and VL gene rep-
ertoires from cDNA, and the second set is used to intro-
duce restriction sites for sub-cloning the genes into
phagemid. In our work, we optimized the protocol such
that only one set of primers are used to both amplify the
genes and introduction of restriction sites, thus reducing
the number of primers by half. Moreover, in all of the pre-
vious reports on the construction of large (109–10) naïve
human libraries, smaller libraries were first created and
then combined together to obtain the larger libraries. For
example, Vaughan's library of 1.4 × 1010 was generated
from three sub-libraries [35], Sheet's library of 6.7 × 109
was generated from two sub-libraries [33], and McCaf-
ferty's library of 1010 was generated from sixteen sub-
libraries [44]. In our work, because of the compact size,
we used only a couple of ligation reactions and electropo-
rations, compare to thirty six [33] to several hundred elec-
troporations [35], and more than twelve ligation reactions
[33] used by others to construct the libraries. Thus, one
can use our method to create a compact phage display
antibody library that is better than other libraries of the
same size, and equally well to larger libraries, with less
time and budget.
The scFv phage library was created by focusing on ampli-
fication of highly diverse re-arranged V genes, as it has
been formerly suggested that the most useful scFv library
are constructed from V-genes rearranged in vivo [33]. In
order to reduce amplification bias we performed 75 inde-
pendent PCR reactions using all possible combinations
within a primer set, modified from previous reports [14].
The high diversity of this compact library came from the
high diversity of re-arranged variable region genes, which
were isolated from one hundred and forty non-immu-
nized healthy donors. This is the highest number of re-
arranged V-gene templates that has ever been reported.
Other reports of large and complex human scFv libraries,
for example, used five [33], forty two [44], forty three [35],
or fifty [47] donors.
The cDNAs from peripheral blood lymphocytes of the 140
non-immunized donors were synthesized using a mix of
random hexamers and oligo dTs, so that all five antibody
classes could be represented. Amplification using these
non-specific primers has been shown to be as efficient as
using germline, VH, IgG or IgM, specific primers for the
construction of efficient naïve repertoires [13,48]. In
order to create scFv fragment genes as a VH-linker-VL type,
the 3' ends of VH genes were made complementary to 5'
ends of VL genes through a (Gly4Ser)3 linker peptide, and
the VH and VL genes were assembled and amplified by
overlap extension followed by pull-through PCR. Moreo-
ver, to ensure the correct overlaps during assembly PCR,
the three (Gly4Ser)3  repeat in the single chain linker
region were encoded by different codons (Figure 2). A
proof reading DNA polymerase was used in the overlap
extension step to ensure the accurate joining of blunt ends
of VH and VL genes segments and in-frame formation of
scFv repertoire. For other steps, TAQ DNA polymerase was
used due to a more efficient amplification using this
polymerase. In addition, the mutations created by ampli-
fication errors could add more diversity to the library. The
primer sets used for the amplification of V gene reper-
toires were designed based on information retrieved from
V-BASE [34] and previous publications [14,32]. The 5'
and 3' ends of each primer incorporated sequences which
could be cleaved by restrictions enzymes, avoiding a two
step amplification procedure as previously reported for a
murine scFv library [32]. It has been previously suggested
that several hundred bps of DNA sequence 5' and 3' of the
scFv cloning sites is required for efficient digestion of the
insert [32,33]; however we found that this is not neces-
sary, provided that the inserts were incubated with the
restriction enzyme for at least 10 hour. In addition to the
shortest list of primer used, the fewest steps were needed
for the generation of the library. This is because only one
ligation step and two electroporation were required, with-
out the creation of sub-libraries as performed by other
strategies [33,35,44].
Utilization of different modified helper phages to
improve the bio-panning efficiency has been reported
[37,49-54]. Here, the helper phage KM13 [37], which is a
protease sensitive helper phage, was used during the bio-
panning. This modified helper phage encodes a modified
gene III, encoding a peptide sequence which will beBMC Biotechnology 2009, 9:6 http://www.biomedcentral.com/1472-6750/9/6
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cleaved by trypsin, between domain D2 and D3. By apply-
ing trypsin cleavage following selection of the phage anti-
body library, the phage particles not carrying an antibody-
pIII fusion would lose all there domain D1 and D2 of pro-
tein 3, and thus lose their ability to infect bacteria;
whereas phage particles carrying an antibody-pIII fusion
would retain their infectivity, due to the absence of the
protease sensitive site in the gene III of the fusion. Thus,
in the bio-panning procedure described here, elution was
done by a combination of low pH treatment with glycine
buffer (pH2.2) and trypsin treatment. Any phagemid
encoded phage display library contain a large proportion
of phage particles devoid of pIII fusion on their surface,
however these can still be retrieved following selection
due to non-specific binding of phage particles. Removal of
phage particles carrying no scFv by trypsin digestion,
greatly improve the efficiency of the selection. We found
that we obtained better result when using KM13 helper
phage than regular helper phage, M13K07 (data not
shown). Utilization of KM13 helper phage also limits the
number of eluted phages after the first round of section
[55], which would be a logic consequence of decreasing
the number of background binders of non-displaying
phage particles and taken together this explain why only
one round of panning is sufficient for most selections
done in this study.
Our compact scFv antibody phage library of 1.5 × 108 scFv
repertoire rendered binders to seven different antigens.
The number of different antibody fragments selected with
each antigen was in the same range as from other naïve
scFv phage display library, even though those libraries are
93 [14] and 44 times [56] larger than ours. Since we aimed
to amplify as many different variable regions as possible,
sequence diversity was confirmed in both the primary
library and the binders retrieved after antigen selection.
The high diversity of our compact scFv library was con-
firmed by DNA sequence analysis of ten randomly picked
clones from unselected library and seven selected clones.
Sequence analysis of the primary library indicated that
variable regions were derived from all six VH and seven VL
gene families. The variable regions derived from VH1, VH3,
VH4, Vκ1, Vκ3, Vλ1, Vλ6 families had been commonly
observed among antibody fragments from phage display
libraries [33,57], and human hybridomas [58]. Besides
variable regions derived from these preferences gene fam-
ilies, other less frequently used V gene families i.e., VH2,
VH5, VH6, Vκ2, Vκ4, Vλ2, Vλ3 and Vλ5 were also found in
our library. These clones were derived from a number of
germ line segments with varied number of amino acid
substitutions, ranging from 0–24, indicating excellent
diversity in our scFv phage library. We observed a prefer-
ence usage of certain V gene segments in unselected
library (VH3DP47, VλDPL16, and Vκ3DPK22) as well as in
the selected clones (VH3DP47, and Vκ1DPK9). This is in
accordance with the bias of gene segments most often
found in nature [17,33,35] The length (5–19) and amino
acid sequence of CDR3 regions varied considerably, even
when the genes came from the same germ line segments.
None of these clones shared the same CDR3 sequence.
These are all characteristic of the creation of naturally
occurring immunoglobulin repertoire [17,35], which
involve somatic recombination during the development
of B cells in the central lymphoid organs, and somatic
hypermutation that operates on B cell in peripheral lym-
phoid organs, resulting in an affinity maturation of the
antibody population [59]. Thus, a highly diverse and
compact antibody library similar to nature could be suc-
cessfully constructed from a large number of V gene reper-
toire templates. It has been estimated that the human
antibody repertoire is at least 1011 [59]; however, the
number of antibody specificities present at any one time
is limited by the total number of B cells in an individual,
as well as by each individual's encounters with antigens,
which is approximately 108 different specificities at any
one time [59]. This is the same diversity of the compact
library described in this paper. Therefore, by performing
one-round of bio-panning with this library, one can
mimic natural selection and obtain a diverse pattern of
binding antibodies.
Even if the size of the library is essential for successful iso-
lation of high affinity antibodies, a very large library is dif-
ficult to maintain [10] and in many case, high affinity is
not necessary the pre-requisite for successful application
of antibody. This is because other properties such as spe-
cificity, expression level and stability are also important.
The affinity of the antibody can be further enhanced by
affinity maturation as previously reported [7,60-65].
These methods involve introduction of diversity into the
antibody genes by various methods of mutagenesis such
as error-prone PCR, DNA or chain shuffling, or oligonu-
cleotide-directed PCR, while affinity selection of the vari-
ants with decreasing amounts of antigens [16]. The
affinity maturation process is useful either for improving
the affinity of antibody that is selected from naive phage
library of medium size (107–8 different clones) that has
lower binding affinity, or for generating "super" antibody
to be used in certain applications, such as diagnostic or
immunotherapy. It has been reported that phage antibod-
ies with approximately tenfold higher affinities (1011 M-1)
[63,66,67] than the ceiling affinity that can be obtained
from in vivo selection of B-cell (1010 M-1) [65] have been
made by in vitro affinity maturation.
The ability to isolate an antibody that can recognize free
Aflatoxin from a simple bio-panning procedure under-
scores the high quality of our compact library. It has been
well known that it is difficult to obtain antibody against
free haptens [65], especially from the naïve library.BMC Biotechnology 2009, 9:6 http://www.biomedcentral.com/1472-6750/9/6
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Recombinant scFv against soluble alfatoxin that has been
generated so far could only be obtained from either an
optimized bio-panning method by elution with soluble
haptens [39], or isolated from hybridoma [41]. The ability
to isolate antibodies that are specific to both conjugated
and free Aflatoxin demonstrated the high quality of this
compact library. It is possible that the population of
donors have been previously exposed to Aflatoxin as it is
a very common contaminant in the region.
In addition to hapten, we also demonstrated successful
selections of specific antibodies against complex antigens,
i.e., crude snake venom, cancer cell surface, and rabies
virus, which are more difficult to obtain. This is because of
the limited amount of target antigen present in the mix-
ture, the background binding, and enrichment of phage
antibodies specific for non-relevance antigens [10]. How-
ever, one cannot rule out the possibility that the apparent
specific binding of antibody to complex target is actually
resulted from the different level of expression of the recog-
nized antigen. Thus, characterization of these selected
antibodies, as well as more investigation to determine the
identities of their specific partners, are needed to be done.
Conclusion
In conclusion, a simple method for the construction of a
compact and efficient human scFv phage library has been
reported. The key to the success of this method is a very
high diversity V-gene repertoire template that was
obtained from 140 non-immunized donors in combina-
tion with optimized primer set and cloning technique.
This method is very practical and should be able to be car-
ried out in any academic institutions, small research facil-
ities, and non-profit organizations world-wide, for the
generation of both naïve and immunized human phage
display scFv library.
Methods
Antigens
Albumin from bovine serum (BSA) was natural purified
protein obtained from Fluka, USA. Crude venom of cobra
(Naja kaouthia) and green pit viper (Trimeresurus albo-
labris) were purchased from the Thai Red Cross Society,
Thailand. Aflatoxin B1-BSA conjugated and soluble Afla-
toxin B1 (Sigma, Germany) were prepared from Aspergillus
flavus. Amylase enzyme Type XII-A (Sigma, Germany) was
prepared from Bacillus licheniformis. Purified Chick
Embryo Cell (PCEC) rabies vaccine strain flury LEP (Chi-
ron Behring, India) were inactivated rabies viruses that
were cultured in primary chicken fibroblast cell. Cholan-
giocarcinoma, cell line (KKU-100), which is an egg-
proven  Opisthorchis-associated cholangiocarcinoma
derived from porta hepatic cells [68], was a gift from Dr.
Banchob Sripa.
Construction of pMod1 phagemid vector
Phage 3.2 vector (Maxim Biotech Inc, USA) was used as a
basis for the construction of pMod1 phagemid vector. The
new vector contains SfiI and NotI restriction sites and
includes a hexahistidine tag and Myc tag. Two oligonucle-
otides, Mod1up (5' TCG ACC CAT GGC TCG AGG CGG
CCG CAC ATC ATC ATC ACC ATC ACG GGG CCG CAG
GGC C 3') and Mod1dn (5' CT GCG GCC CCG TGA TGG
TGA TGA TGA TGT GCG GCC GCC TCG AGC CAT GGG
3') were annealed and ligated into the phage 3.2 vector
(Figure 1) for the generation of pMod1. The insertion was
made at ApaI/SalI sites using T4 DNA ligase (NEB, USA).
The finished pMod1 vector was amplified by transforming
E. coli DH5αF', and the phagemid DNA was prepared by
miniprep extraction kit (Qiagen, Germany). The integrity
of the plasmid was confirmed by automated DNA
sequence analysis (Macrogen, Korea).
Construction of human scFv phage library
Generation of scFv gene repertoire
The peripheral blood donations from one hundred and
forty healthy, non-immunized donors were collected into
four pools, according to different blood groups. These
blood samples were tested negative and discharged from
the Thai Red Cross Society blood donation unit in
Nakhon Ratchasima province. Total RNA was prepared
from the B lymphocytes and pooled together. Approxi-
mately 2 ml of blood samples from each donor were col-
lected into four pools, according to different blood groups
(blood group A, B, O and AB). Thus, a total of approxi-
mately 280 ml of blood sample was used. B-lymphocytes
were isolated from peripheral blood by using Ficoll
plaque reagent (Amersham, USA). Briefly, the diluted
blood sample (1:1 of blood per PBS) was carefully layered
on top of the Ficoll plaque reagent, and then the two-
phase solution was centrifuged at 400 × g for 30 minutes.
B-lymphocytes were collected from the interface between
the two phases. The interface contamination such as plate-
lets and plasma proteins were removed by washing with
PBS. Total RNA was extracted from B-lymphocytes by TRI-
zol reagent (Invitrogen, USA). B-lymphocytes were resus-
pended in 1 ml TRIzol and incubated at 65°C for 15
minutes with occasional inversion of the tube. After add-
ing 0.2 ml of chloroform, the tube was vortexed for 15 sec-
onds and then centrifuged at 12,000 × g for 15 minutes at
4°C. The aqueous phase was transferred to a new tube
containing 1 μl of RnaseOut (40 U/μl, Invitrogen, USA),
and 0.5 ml of isopropanol was added to precipitate RNA.
The tube was incubated at room temperature for 10 min-
utes. The precipitated RNA was pelleted by centrifugation
at 12,000 × g  for 15 minutes at 4°C. The pellet was
washed with 0.5 ml of 75% ethanol and then centrifuged
at 12,000 × g for 15 minutes at 4°C. After the supernatant
was removed, the pellet was air dried for 5 minutes at
room temperature and dissolved in sterile deionizedBMC Biotechnology 2009, 9:6 http://www.biomedcentral.com/1472-6750/9/6
Page 13 of 16
(page number not for citation purposes)
water. Then 1 μl of RnaseOut (40 U/μl, Invitrogen, USA)
was added into total RNA and stored at -70°C. First strand
cDNA was generated from 10 μg of total RNA, using
MMuLV reverse transcriptase (NEB, USA) with a mix of 20
μM of oligo-dT18 and 8 ng of random hexamer primer.
The genes for variable regions of heavy chain, κ light
chain, and λ light chain (VH, Vκ, and Vλ) were amplified
separately and recombined by three subsequent PCR reac-
tions. The first set of PCR consists of 75 independent reac-
tions to generate variable domains of the heavy and light
chains. The heavy chain 5' primers were designed to
include a SfiI site, and the light chain 3' primers include a
NotI site. Light chain 5' primers were designed to include
part of the linker region (Gly4Ser)3 and compatible with
the heavy chain 3' primers (Table 1). Each variable region
gene was separately amplified using hot start PCR in a
reaction of 50 μl containing 5 μl cDNA and 1 μM of each
5' and 3' primer. This reaction was performed using the
Taq polymerase (NEB, USA). The samples were heat at
94°C for 5 min, followed by 35 cycles of 94°C for 1 min,
55–65°C for 1 min, 72°C for 2 min. The final extension
was performed at 72°C for 10 min. Equal amount of PCR
products were pooled into collections of VH, Vκ, and Vλ
gene repertoire, and purified from the low melting tem-
perature agarose gel according to standard protocol [69].
In the second PCR, heavy and light chains were assembled
and amplified using pfu  DNA Polymerase (Promaga,
USA). The assembly PCR reaction contained equal molar
mixture of the pooled heavy (VH) DNA and pooled light
(Vκ, or Vλ) gene repertoire. The assembly reaction was
cycled 5 times (94°C for 45 s, 60°C for 50 s, and 72°C for
60 s) without primers. The third reaction created a full-
length scFv gene repertoire from the second PCR by PCR
amplification in the presence of pull-through primers.
This PCR extended the scFv gene from the SfiI and NotI
sites flanking scFv genes, using the following primers:
PTfw (5'-CCT TTC TAT GCG GCC CAG CCG GCC ATG
GCC-3') and PTrv (5'-CAG TCA TTC TCG ACT TGC GGC
CGC ACG-3'). The reaction was performed using the Taq
polymerase and 1 μl of assembled products from the sec-
ond PCR. This pull-through PCR was cycled 30 times
(94°C for 1 min, 60°C for 1 min, 72°C for 2 min), and a
final extension at 72°C for 10 min. Then the samples were
purified by a QIAquick PCR Purification Kit (QIAGEN,
Germany) for the next step.
Cloning of the scFv into pMod1 vector
The amplified scFv DNA and pMod1 phagemid vector
were sequentially digested with NotI and SfiI, by incubat-
ing at appropriate conditions for 10 hrs. The cut vector
was then de-phosphorylated with calf intestinal phos-
phatase (NEB, USA) and gel-purified using Wizard® DNA
Clean-Up System (Promega, USA) before ligation. A total
of 2.8 μg of digested scFv DNA were ligated into 5.5 μg of
pMod1 phagemid vector, at a vector: insert molar ratio of
1:3, to generate the scFv-gene III fusion library. The liga-
tion was done using T4 DNA ligase (NEB, USA) overnight
at 16°C. Ligated DNA populations were electroporated
into  Escherichia coli (E. coli) TG1 (Maxim Biotech Inc,
USA) using an Eppendrof 2510 electroporator (Eppen-
drof, USA). The transformed cells were then incubated for
1 hour at 37°C before spreading on TYE plate containing
ampicillin (100 μg/mL) and glucose (1% w/v), the plate
was incubated overnight at 37°C. Complexity of the
library was determined at this step by serially diluting the
transformed cells and counting the number of colonies.
Ligation efficiency was also determined by counting the
number of colonies from no-insert ligation. Colonies
were then collected, mixed with glycerol, and stored at -
80°C. The library stock was grown to log phase and res-
cued with M13KO7 helper phage (Maxim Biotech Inc,
USA). Recombinant phage preparations were purified and
concentrated by polyethylene glycol (PEG) precipitation
before keeping at -80°C.
Determination of library size
A total of 8.3 μg of DNA was electroporated in to E.coli
TG1 to generate the scFv phage library. After electropora-
tion the cuvette was flushed with 6 ml of SOC medium
and transformed cells were incubated for 1 hour at 37°C
before spreading on TYE plate containing ampicillin (100
μg/mL) and glucose (1% w/v), then the plate was incu-
bated overnight at 37°C. Complexity of the library was
determined by serially diluting the transformed cells and
counting the number of colonies. A volume of 100 μl
from transformation reactions was taken and a four step
10-fold serial dilution was made. The 100 μl of each dilu-
tion was plated out. The appearance of 250 individual col-
onies from 104 dilution titer indicated a library diversity
of 1.5 × 108.
Selection of phage antibody library
Selection of phage particles displaying specific scFv frag-
ments were performed on Immuno 96 MicroWell™ Plates
(Nunc, Denmark). The different protein antigens (50–600
μg/ml) in phosphate-buffered saline (PBS) (or 0.1 mM
NaHCO3, in case of amylase) were coated on the plates
overnight at 4°C (in case of Rabies, the preparation was
first incubated at 37°C for 2 hrs). For cholangiocarcinoma
cell surface, approximately 5 × 105cells growing in a 5-ml
flask was used. Following blocking with 2% (w/v)
skimmed milk powder in PBS (2% MPBS), a library con-
taining between 1011 and 1012 phage particles were added
and the plate was incubated for 2 hours at room tempera-
ture (RT; 25–28°C). Non-bound phages were eliminated
by washing 10–20 times with PBS containing 0.1% Tween
20 (PBS-T), followed by 10–20 times washing with PBS.
The bound phages were eluted by incubation with 50 μl
of 1 μg/μl trypsin for 10 min, followed by 50 μl of 50 mM
glycine- HCl pH 2.0 (immediately neutralized with 50 μlBMC Biotechnology 2009, 9:6 http://www.biomedcentral.com/1472-6750/9/6
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of 200 mM NaHPO4, pH7.5 after 10 min). Eluted phages
were used to infect exponentially growing E.coli TG1 cells
by incubating for 30 min at 37°C. Infected cells were
spread on TYE plate containing ampicillin (100 μg/mL)
and glucose (1% w/v), then the plate was incubated over-
night at 37°C. Individual phage-infected colonies were
picked and grown for production of phagemid particles in
96-well plate. The culture was rescued using either
M13KO7 or KM13 helper phage (MRC HGMP Resource
Centre, Cambridge, UK) as describe elsewhere [55]. Res-
cued phage particles were used to test their antigen recog-
nition properties by ELISA or to initiate subsequent
rounds of selection using the similar conditions. Between
one and two rounds of selection were performed for each
antigen.
ELISA screening of selected clones
In order to detect antigen recognition, Immuno 96 Micro-
Well™ Plates were coated with approximately 5–200 μg/
ml of each antigen. For cholangiocarcinoma, the cells
were fixed with 4% paraformaldehyde in 96-well tissue
culture plate. After overnight incubation at 4°C, plates
were blocked with 2% MPBS for 1 hour at RT followed by
three washes with PBS. The selected phage preparation
was diluted 1:2 in 4% MPBS before adding into each well,
and incubated for 1 hour at RT. The plates were washed
three times with PBS-T, followed by three times with PBS,
and incubated with a 1:5,000 dilution of a mouse anti-
M13 phage-horseradish peroxidase (HRP) conjugate
(Amersham-Pharmacia Biotech, Sweden) in 2% MPBS.
The plates were washed again as described earlier. The
ABTS (2,2-azino-di-3-ethyl-benzthiazoine-6-sulfonate)
peroxidase substrate (Fluka, USA) was added, and the
absorbance was read at 405 nm, using a Sunrise absorb-
ance reader (TECAN, Austria).
Inhibition ELISA
The inhibition ELISA was performed as described in the
normal ELISA method, except that the phage particles
were pre-incubated in the presence of increasing amount
of soluble Aflatoxin B1 from 0.039–5.0 μg/ml.
DNA fingerprint analysis and DNA sequencing
The diversity of the selected scFv clones was analyzed by
comparing restriction enzyme digestion patterns, a proce-
dure called DNA fingerprinting. The scFv sequence of
individual clones was amplified by PCR using the follow-
ing primers: PTfw (5'-CCT TTC TAT GCG GCC CAG CCG
GCC ATG GCC-3') and PTrv (5'-CAG TCA TTC TCG ACT
TGC GGC CGC ACG-3'). The amplified product was
digested with a frequent cutting enzyme, BstNI (NEB,
USA) and analyzed on 2% agarose gels. For DNA sequenc-
ing, plasmid DNA from different clones was purified
using MiniPreps kit (QIAGEN, Germany) and the inserts
were sequenced using the dideoxynucleotide chain-termi-
nation method with -96gIII primer (5'-CCC TCA TAG TTA
GCG TAA CG-3'), corresponding to the vector sequence
downstream of the scFv gene. After the amino acid
sequences were translated, they were analyzed by using
IgBLAST [36] and V BASE [34] software.
Soluble scFv antibodies production
E. coli HB2151 (Maxim Biotech Inc, USA) cells carrying
the phagemid encoding the scFv antibody were grown in
10 ml of 2 × TY medium containing ampicillin (100 μg/
mL) and glucose (1% w/v). After reaching an OD600 of
0.9, cells were harvested and grown at 30°C in glucose
free 2 × TY medium containing 100 μg/mL ampicillin and
0.1 mM isopropyl-μ-d-thiogalactopyranoside (IPTG). The
cell culture supernatant containing scFv were collected
after induction for 20 hours. In some case, the cell lysate
containing scFv were extracted after induction for 6 hours.
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